On the other hand, short‐term (1 month) and long‐term (6 months) administration of dapagliflozin, another SGLT2 inhibitor with known anti‐arrhythmic impacts on cardiac ionic currents (Müller et al. 2024; Paasche et al. 2024; Philippaert et al. 2021), exhibited mostly promising outcomes in lowering EAT in T2DM patients with or without CAD (Braha et al. 2019; Cinti et al. 2023; Iacobellis and Gra‐Menendez 2020; Macías‐Cervantes et al. 2024; Sato et al. 2020; Song et al. 2023). Here, SLC5A2 is linked to type 2 diabetes mellitus.